论文部分内容阅读
目的:通过观察律复康胶囊对哇巴因致豚鼠心律失常模型的对抗作用,为临床用药提供依据。方法:取实验豚鼠50只,均分为模型对照组(等容量纯化水)、阳性对照组(4.185g.kg-1)、律复康胶囊小剂量(1.539g生药/kg)、中剂量(3.078g生药/kg)、大剂量(6.156g生药/kg)组,各组豚鼠按剂量连续给药3d,末次药后30min,用哇巴因致豚鼠心律失常模型,用Medlab生物信号采集处理系统记录豚鼠插肢体电极检测标准Ⅱ导心电图,分别记录出现室性早搏、心室颤动和心脏停搏时哇巴因用量。结果:律复康胶囊各剂量组豚鼠出现早搏、室颤和停博时所需哇巴因的剂量显著提高,与模型组比有显著性差异(P<0.01或P<0.05)。结论:律复康胶囊能够显著增加诱发豚鼠出现心律失常时哇巴因的剂量,说明律复康胶囊对哇巴因诱发的心律失常有一定对抗作用。
OBJECTIVE: To observe the antagonistic effect of L-Fu-Kang capsules on ouabain-induced arrhythmia in guinea pigs and provide basis for clinical drug use. METHODS: Fifty guinea pigs were randomly divided into model control group (equal volume purified water), positive control group (4.185g.kg-1), LFP capsule low dose (1.539g crude drug/kg), medium dose ( 3.078g crude drug/kg), large dose (6.156g crude drug/kg) group, guinea pigs in each group were continuously dosed for 3 days, 30min after the last drug, guinea pig arrhythmia model was induced by ouabain, and Medlab biological signal acquisition and processing system was used. The guinea pig plug electrode test standard II lead electrocardiogram was recorded to record the ouabain dosage in the presence of ventricular premature beats, ventricular fibrillation and cardiac arrest. RESULTS: The dose of ouabain required for premature beats, ventricular fibrillation and stoppage of guinea pigs in each dose group of Lfukang capsules was significantly increased, which was significantly different from that in the model group (P<0.01 or P<0.05). Conclusion: Lfukang capsule can significantly increase the dose of ouabain when arrhythmias are induced in guinea pigs, indicating that Lfukang capsule has a certain antagonistic effect on ouabain-induced arrhythmia.